Living with advanced gastroesophageal cancer means facing a difficult road ahead. For patients whose tumors cannot be removed by surgery, finding a treatment that works effectively is vital. New data suggests that adding immunotherapy to a standard chemotherapy regimen can improve both the length of time patients live and the time they live without their cancer progressing.
Researchers looked at data from over 6,600 patients to compare these treatments. They found that the combination of immunotherapy and chemotherapy performed better than using chemotherapy by itself. Specifically, the study looked at a type of immunotherapy called a PD-1 inhibitor. Among these options, a specific drug called sintilimab showed more efficacy when paired with chemotherapy than other similar treatments.
While the combination treatment can cause more side effects than chemotherapy alone, these effects were described as manageable. However, it is important to note that the specific data regarding sintilimab's safety and success came from indirect comparisons. Because of this, the evidence for that specific drug is less certain than other parts of the study.
